ClinicalTrials.gg
TerminatedNCT03251924Updated Feb 28, 2023Results posted

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of BMS-986226 and Nivolumab in Cancer, Tumors and Neoplasm, sponsored by Bristol-Myers Squibb. Terminated at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.

02

Conditions studied

  • Cancer
  • Tumors
  • Neoplasm
  • Malignancy

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 80 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Advanced solid tumors
  • Histological or cytological confirmation of a that is advanced ( and/or unresectable) with measureable disease as defined by (RECIST) v1.1 or PCWG3 (prostate only).
  • At least 1 lesion accessible for in addition to the target lesion
  • Participants must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen
  • (ECOG) performance status ≤2

Exclusion criteria

Exclusion Criteria:

  • Participants with active central nervous system (CNS) , untreated , or with the CNS as the only site of disease are excluded (controlled brain metastases will be allowed to enroll)
  • Participants with carcinomatous meningitis
  • Prior active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
  • Active, known, or suspected disease
  • Uncontrolled or significant cardiovascular disease
  • Participants with known allergies to egg products, neomycin and tetanus toxoid.
  • Prior adverse reaction to tetanus toxoid- containing vaccines.

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    BMS-986226

    administered intravenously

    Drug: BMS-986226 · Biological: Tetanus Vaccine

  • Experimental
    BMS-986226 and Nivolumab

    administered intravenously

    Drug: BMS-986226 · Biological: Nivolumab · Biological: Tetanus Vaccine

  • Experimental
    BMS-986226 and Ipilimumab

    administered intravenously

    Drug: BMS-986226 · Biological: Ipilimumab · Biological: Tetanus Vaccine

Interventions

  • DrugBMS-986226

    specified dose on specified days

  • BiologicalNivolumab

    specified dose on specified days

    Also known as: BMS-936558, PD-1 receptor blocking monoclonal antibody [mAb], Opdivo

  • BiologicalIpilimumab

    specified dose on specified days

    Also known as: BMS-734016, MDX010, Checkpoint blocking antibody that recognizes CTLA-4, Yervoy

  • BiologicalTetanus Vaccine

    specified dose on specified days

06

What researchers measure

Primary outcomes

  1. The Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose up to 100 days post last dose, up to approximately 31 months

  2. The Number of Participants Experiencing Serious Adverse Events (SAEs)

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose up to 100 days post last dose, up to approximately 31 months

  3. The Number of Participants Experiencing Adverse Events (AEs) Meeting Dose Limiting Toxicity (DLT) Criteria

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Dose limiting toxicity (DLT) is defined based on the incidence, intensity, and duration of AEs for which no clear alternative cause is identified. The DLT period will be 28 days (4 weeks) in the Preliminary Safety Cohorts. Any toxicities that occur beyond the 4-week DLT period will also be considered in dose-level decisions. For the purpose of participant management, any AE that meets DLT criteria, regardless of the cycle in which it occurs, will lead to discontinuation of study treatment. AEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

    Time frame: From first dose up to 100 days post last dose, up to approximately 31 months

  4. The Number of Participants Experiencing Adverse Events Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose up to 100 days post last dose, up to approximately 31 months

  5. The Number of Participants Experiencing Adverse Events Resulting in Death

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose up to 100 days post last dose, up to approximately 31 months

  6. The Number of Participants Experiencing Clinical Laboratory Abnormalities

    The number of participants experiencing abnormal laboratory results of Grade 3 or higher. Laboratory values will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 with Grade 3=severe and Grade 4=life threatening.

    Time frame: From first dose up to 30 days post last dose (approximately 28 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) as assessed by investigator per RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. BOR for a participant is defined as the best response designation recorded between the date of first dose (or date of randomization) and the date of first objectively documented progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.

    Time frame: From first dose up to documented disease progression, up to 48 months

  2. Median Duration of Response (DOR)

    DOR for a participant with confirmed response is defined as the time from the date of first response CR or PR to the date of first objectively documented tumor progression as determined using RECIST v1.1 or death due to any cause, whichever occurs first. Participant who remain alive and have not progressed will be censored on the date of their last tumor assessment. Participants who started subsequent anticancer therapy without a prior reported progression will be censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose up to the date of the first objectively documented tumor progression or death, whichever occurs first (up to approximately 24 months)

  3. Progression Free Survival (PFS) Rate at 24 Weeks

    The PFSR is defined as the Kaplan Meier estimate of percentage of treated participants remaining progression free and surviving at the prespecified timepoint of 24 weeks since the first dosing date. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also considered progression.)

    Time frame: At 24 weeks

  4. Number of Participants With Anti-Drug Antibodies (ADA) for BMS-986226

    ADA for BMS-986226 is defined as the number of participants found to have seroconverted or boosted their pre-existing ADA during the study period. Baseline ADA positive is defined as ADA is detected in the last sample before initiation of treatment. ADA positive is defined as 1) an ADA detected (positive seroconversion) sample in a participant for whom ADA is not detected at baseline, or (2) an ADA detected sample with ADA titer to be at least 4-fold or greater (≥) than baseline positive titer.

    Time frame: Predose on cycles 1-6, post dose on C1D15, and 30, 60, and 100 days post last dose (up to approximately 31 months)

  5. Changes From Baseline in Cell Surface ICOS Expression on T Cells

    Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in cell surface Inducible Costimulator (ICOS) expression on T cells. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.

    Time frame: From baseline up to pre-dose and 4 hours post dose on C1D1 and pre-dose and 4 hours post dose on C2D1 (approximately 31 months)

  6. Changes From Baseline in ICOS Ligand+ B Cells

    Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in ICOS ligand+ B cells in the tumor and peripheral blood. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.

    Time frame: From baseline up to pre-dose and 4 hours post dose on C1D1, 72 hours post dose on C1D4, and pre-dose on C2D1 (approximately 31 months)

  7. Maximum Observed Plasma Concentration (Cmax)

    Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)

  8. Effective Elimination Half-Life (T-HALFeff)

    Effective elimination half-life that explains the degree of accumulation observed

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C2D1 and C3D1 (approximately 31 months)

  9. Trough Observed Serum Concentrations (Ctrough)

    Trough observed serum concentrations (Ctrough) is defined as the concentration reached by a drug immediately before the next dose is administered

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. Pre-dose on C5D1 and C6D1. Pre-dose and 0.5 hours post dose on C7D1. (approximately 31 months)

  10. Time of Maximum Observed Serum Concentration (Tmax)

    Tmax is defined as the amount of time that a drug is present at the maximum concentration in serum

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)

  11. Area Under Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC (0-T)]

    AUC(0-t) (partial AUC) is defined as the area under the concentration-time curve from dosing (time 0) to time t. AUC(0-t) may be computed for one or more values of t, with specific values of t determined after observing the data.

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)

  12. Area Under the Concentration-Time Curve in 1 Dosing Interval [AUC (TAU)]

    AUC (TAU) is defined as the area under the plasma concentration-time curve from time zero to the end of the dosing interval

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)

  13. Total Body Clearance (CLT)

    CLT is defined as the elimination of the drug from the body

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)

  14. Average Concentration Over a Dosing Interval (Css-avg)

    Css-avg is defined as the average concentration over a dosing interval (AUC\[TAU\]/tau) Note: Coefficient of variation is reported in lieu of geometric coefficient of variation

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)

  15. Accumulation Index - Area Under Curve (AI-AUC)

    Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. The area under curve is defined as the area under the plot of plasma concentration of a drug versus time after dosage which reflects the extent of exposure to a drug and its clearance rate from the body.

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)

  16. Accumulation Index - Cmax (AI-Cmax)

    Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. (Approximately 31 months)

  17. Accumulation Index - Concentrations at the End of Dosing Interval (AI-CTAU)

    Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose.

    Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. (Approximately 31 months)

07

Results

Posted Feb 28, 2023
Limitations and caveats
Study CA021002 was terminated because the Sponsor discontinued further development of BMS-986226. The decision for the study closure was not related to any safety concerns associated with BMS-986226.

Participant flow

Participant flow — Overall Study
MilestonePreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Started677119910129
Completed000000311
Not completed67711997118
Withdrew: Disease progression6678876106
Withdrew: Adverse event unrelated to study drug000101100
Withdrew: Death010111000
Withdrew: Study drug toxicity000100001
Withdrew: Other reasons000000001
Withdrew: Participant request to discontinue study treatment000000010

Outcome measures

PrimaryThe Number of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose up to 100 days post last dose, up to approximately 31 months
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs)
ParticipantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
The Number of Participants Experiencing Adverse Events (AEs)677119910129
PrimaryThe Number of Participants Experiencing Serious Adverse Events (SAEs)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose up to 100 days post last dose, up to approximately 31 months
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
The Number of Participants Experiencing Serious Adverse Events (SAEs)2321059595
PrimaryThe Number of Participants Experiencing Adverse Events (AEs) Meeting Dose Limiting Toxicity (DLT) Criteria

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Dose limiting toxicity (DLT) is defined based on the incidence, intensity, and duration of AEs for which no clear alternative cause is identified. The DLT period will be 28 days (4 weeks) in the Preliminary Safety Cohorts. Any toxicities that occur beyond the 4-week DLT period will also be considered in dose-level decisions. For the purpose of participant management, any AE that meets DLT criteria, regardless of the cycle in which it occurs, will lead to discontinuation of study treatment. AEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

Time frame:
From first dose up to 100 days post last dose, up to approximately 31 months
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs) Meeting Dose Limiting Toxicity (DLT) Criteria
ParticipantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
The Number of Participants Experiencing Adverse Events (AEs) Meeting Dose Limiting Toxicity (DLT) Criteria000100010
PrimaryThe Number of Participants Experiencing Adverse Events Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose up to 100 days post last dose, up to approximately 31 months
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events Leading to Discontinuation
ParticipantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
The Number of Participants Experiencing Adverse Events Leading to Discontinuation000114032
PrimaryThe Number of Participants Experiencing Adverse Events Resulting in Death

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose up to 100 days post last dose, up to approximately 31 months
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events Resulting in Death
ParticipantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
The Number of Participants Experiencing Adverse Events Resulting in Death535857785
PrimaryThe Number of Participants Experiencing Clinical Laboratory Abnormalities

The number of participants experiencing abnormal laboratory results of Grade 3 or higher. Laboratory values will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 with Grade 3=severe and Grade 4=life threatening.

Time frame:
From first dose up to 30 days post last dose (approximately 28 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Clinical Laboratory Abnormalities
ParticipantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
HEMOGLOBIN100112011
LYMPHOCYTES (ABSOLUTE)011323243
LYMPHOCYTES (RELATIVE)010001100
ALKALINE PHOSPHATASE000212320
ASPARTATE AMINOTRANSFERASE000110111
ALANINE AMINOTRANSFERASE000010101
G-GLUTAMYL TRANSFERASE121432631
BILIRUBIN, TOTAL000210000
PHOSPHATE000001011
LIPASE, TOTAL011000211
HYPONATREMIA000011001
HYPERKALEMIA000100000
HYPERGLYCEMIA100000000
HYPOKALEMIA000000100
SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) as assessed by investigator per RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. BOR for a participant is defined as the best response designation recorded between the date of first dose (or date of randomization) and the date of first objectively documented progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.

Time frame:
From first dose up to documented disease progression, up to 48 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Objective Response Rate (ORR)0 (0.0 to 45.9)0 (0.0 to 41.0)0 (0.0 to 41.0)0 (0.0 to 28.5)0 (0.0 to 33.6)0 (0.0 to 33.6)0 (0.0 to 30.8)8.3 (0.2 to 38.5)0 (0.0 to 33.6)
SecondaryMedian Duration of Response (DOR)

DOR for a participant with confirmed response is defined as the time from the date of first response CR or PR to the date of first objectively documented tumor progression as determined using RECIST v1.1 or death due to any cause, whichever occurs first. Participant who remain alive and have not progressed will be censored on the date of their last tumor assessment. Participants who started subsequent anticancer therapy without a prior reported progression will be censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose up to the date of the first objectively documented tumor progression or death, whichever occurs first (up to approximately 24 months)
Reported as:
Median · Months
Median Duration of Response (DOR)
MonthsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Median Duration of Response (DOR)———————NA (23.4 to 23.4)—
SecondaryProgression Free Survival (PFS) Rate at 24 Weeks

The PFSR is defined as the Kaplan Meier estimate of percentage of treated participants remaining progression free and surviving at the prespecified timepoint of 24 weeks since the first dosing date. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also considered progression.)

Time frame:
At 24 weeks
Reported as:
Number · Percentage of participants
Progression Free Survival (PFS) Rate at 24 Weeks
Percentage of participantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Progression Free Survival (PFS) Rate at 24 Weeks16.7 (0.8 to 51.7)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)8.3 (0.5 to 31.1)18.8 (1.1 to 53.5)
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA) for BMS-986226

ADA for BMS-986226 is defined as the number of participants found to have seroconverted or boosted their pre-existing ADA during the study period. Baseline ADA positive is defined as ADA is detected in the last sample before initiation of treatment. ADA positive is defined as 1) an ADA detected (positive seroconversion) sample in a participant for whom ADA is not detected at baseline, or (2) an ADA detected sample with ADA titer to be at least 4-fold or greater (≥) than baseline positive titer.

Time frame:
Predose on cycles 1-6, post dose on C1D15, and 30, 60, and 100 days post last dose (up to approximately 31 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA) for BMS-986226
ParticipantsPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Baseline ADA Positive000101000
ADA Positive after initiation of treatment463844898
SecondaryChanges From Baseline in Cell Surface ICOS Expression on T Cells

Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in cell surface Inducible Costimulator (ICOS) expression on T cells. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.

Time frame:
From baseline up to pre-dose and 4 hours post dose on C1D1 and pre-dose and 4 hours post dose on C2D1 (approximately 31 months)
Reported as:
Median · Median of Fluorescence of ICOS (MFI)
Changes From Baseline in Cell Surface ICOS Expression on T Cells
Median of Fluorescence of ICOS (MFI)Preliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Baseline Response985.5 (554 to 1243)659.0 (455 to 775)878.0 (599 to 1361)482 (197 to 912)434.0 (169 to 884)634.0 (94 to 1166)592.0 (162 to 933)714.0 (234 to 1438)506.5 (20 to 943)
C1D1- Pre-Dose-394.0 (-394 to 394)————-636.0 (-636 to -636)———
C1D1- 4 hours post dose-1049.0 (-1049 to -1049)-603.0 (-603 to -603)-762.0 (-847 to -565)-391.0 (-635 to -176)-324.0 (-481 to -95)-545.0 (-1029 to -184)-382.5 (-649 to -116)-654.5 (-1405 to -214)-490.0 (-928 to -429)
C2D1- Pre-Dose-421.0 (-729 to -31)-26.0 (-538 to 104)-414.0 (-1101 to 630)-153.0 (-774 to -38)-185.0 (-865 to -177)-627.0 (-632 to -622)-294.0 (-500 to 308)-185.5 (-1155 to 430)11.5 (-104 to 148)
C2D1- 4 hours post dose———-167.5 (-229 to -106)-336.5 (-507 to -166)-567.0 (-615 to -372)——-465.5 (-911 to 254)
SecondaryChanges From Baseline in ICOS Ligand+ B Cells

Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in ICOS ligand+ B cells in the tumor and peripheral blood. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.

Time frame:
From baseline up to pre-dose and 4 hours post dose on C1D1, 72 hours post dose on C1D4, and pre-dose on C2D1 (approximately 31 months)
Reported as:
Median · Median of Fluorescence of ICOS (MFI)
Changes From Baseline in ICOS Ligand+ B Cells
Median of Fluorescence of ICOS (MFI)Preliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Baseline Response-9.0 (-94 to 185)-33.0 (-70 to 67)2.5 (-99 to 95)40.5 (-90 to 127)-60.5 (-171 to 74)57.0 (-100 to 182)-15.0 (-79 to 70)-11.5 (-113 to 41)39.0 (-56 to 103)
C1D1 - 4 hours post dose-106.0 (-106 to -106)-2.0 (-2 to -2)-3.0 (-48 to 37)1.0 (-9 to 23)-13.5 (-55 to 0)9.5 (-16 to 99)3.5 (1 to 6)0.0 (-14 to 37)-6.0 (-21 to 40)
C1D4- 72 hours post dose11.0 (-181 to 58)102.0 (-28 to 190)170.0 (118 to 210)37.0 (-143 to 231)64.5 (-71 to 127)29.0 (-106 to 88)90.0 (17 to 163)70.0 (3 to 143)33.5 (-28 to 121)
C2D1- Pre dose-4.0 (-267 to 54)-24.0 (-211 to 24)96.0 (-167 to 207)-17.0 (-100 to 170)103.5 (-39 to 216)-28.0 (-74 to 18)-9.0 (-129 to 83)61.5 (-20 to 186)-17.0 (-175 to 103)
SecondaryMaximum Observed Plasma Concentration (Cmax)

Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C1D1733 ± NA2250 ± NA6609 ± NA19524 ± NA41698 ± NA85905 ± NA5440 ± NA43309 ± NA3451 ± NA
C2D1—1050 ± NA7220 ± NA23322 ± NA45054 ± NA91931 ± NA—30200 ± NA2697 ± NA
C3D1—1060 ± NA3168 ± NA15000 ± NA41700 ± NA76700 ± NA——3880 ± NA
SecondaryEffective Elimination Half-Life (T-HALFeff)

Effective elimination half-life that explains the degree of accumulation observed

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C2D1 and C3D1 (approximately 31 months)
Reported as:
Mean · Hours
Effective Elimination Half-Life (T-HALFeff)
HoursPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C2D1———212 ± 9.4102 ± NA————
C3D1————308 ± NA————
SecondaryTrough Observed Serum Concentrations (Ctrough)

Trough observed serum concentrations (Ctrough) is defined as the concentration reached by a drug immediately before the next dose is administered

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. Pre-dose on C5D1 and C6D1. Pre-dose and 0.5 hours post dose on C7D1. (approximately 31 months)
Reported as:
Mean · ng/mL
Trough Observed Serum Concentrations (Ctrough)
ng/mLPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
Cycle 2 Day 1—12.5 ± NA27.0 ± NA943 ± 584.41501 ± 1202.91491 ± 1287.312.5 ± NA—12.5 ± NA
Cycle 3 Day 1—12.5 ± NA27.2 ± 20.72892 ± NA180 ± NA3150 ± NA12.5 ± NA—12.5 ± NA
Cycle 4 Day 112.5 ± NA—12.5 ± NA504 ± NA800 ± 401.1—12.5 ± NA—12.5 ± NA
Cycle 5 Day 112.5 ± NA———3300 ± NA———12.5 ± NA
Cycle 6 Day 112.5 ± NA————————
Cycle 7 Day 1———————12.5 ± NA12.5 ± NA
SecondaryTime of Maximum Observed Serum Concentration (Tmax)

Tmax is defined as the amount of time that a drug is present at the maximum concentration in serum

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Reported as:
Median · Hours
Time of Maximum Observed Serum Concentration (Tmax)
HoursPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C1D14.00 (0.067 to 4.22)0.283 (0.133 to 4.00)0.534 (0.467 to 4.50)1.25 (0.467 to 21.7)3.88 (0.467 to 24.0)4.00 (0.500 to 24.0)2.88 (0.467 to 4.50)1.02 (0.483 to 18.9)0.600 (0.467 to 22.0)
C2D1—0.600 (0.600 to 0.600)0.967 (0.967 to 0.967)4.00 (0.483 to 4.00)1.00 (0.433 to 4.52)4.00 (0.383 to 4.00)—2.83 (2.83 to 2.83)2.24 (0.483 to 4.00)
C3D1—0.133 (0.133 to 0.133)0.534 (0.517 to 0.550)0.467 (0.467 to 0.467)1.03 (1.03 to 1.03)0.967 (0.967 to 0.967)——0.500 (0.500 to 0.500)
SecondaryArea Under Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC (0-T)]

AUC(0-t) (partial AUC) is defined as the area under the concentration-time curve from dosing (time 0) to time t. AUC(0-t) may be computed for one or more values of t, with specific values of t determined after observing the data.

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Reported as:
Geometric mean · h*ng/mL
Area Under Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC (0-T)]
h*ng/mLPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C1D133704 ± NA175228 ± NA682168 ± NA1951486 ± NA4966612 ± NA8346408 ± NA370356 ± NA4805561 ± NA277927 ± NA
C2D1—13921 ± NA933038 ± NA3534177 ± NA5887547 ± NA4070442 ± NA—2528949 ± NA35464 ± NA
C3D1—18442 ± NA81982 ± NA2727643 ± NA5157593 ± NA7511434 ± NA——55178 ± NA
SecondaryArea Under the Concentration-Time Curve in 1 Dosing Interval [AUC (TAU)]

AUC (TAU) is defined as the area under the plasma concentration-time curve from time zero to the end of the dosing interval

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-Time Curve in 1 Dosing Interval [AUC (TAU)]
h*ng/mLPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C1D137392 ± NA189031 ± NA704072 ± NA1992589 ± NA5148217 ± NA8740936 ± NA404651 ± NA5006775 ± NA301365 ± NA
C2D1——933038 ± NA3693517 ± NA5766681 ± NA10833374 ± NA———
C3D1—19007 ± NA373429 ± NA2727643 ± NA5157593 ± NA————
SecondaryTotal Body Clearance (CLT)

CLT is defined as the elimination of the drug from the body

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Reported as:
Geometric mean · mL/h
Total Body Clearance (CLT)
mL/hPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C2D1——26.8 ± NA21.7 ± NA34.7 ± NA36.9 ± NA———
C3D1—421 ± NA—29.3 ± NA38.8 ± NA————
SecondaryAverage Concentration Over a Dosing Interval (Css-avg)

Css-avg is defined as the average concentration over a dosing interval (AUC\[TAU\]/tau) Note: Coefficient of variation is reported in lieu of geometric coefficient of variation

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Reported as:
Geometric mean · ng/mL
Average Concentration Over a Dosing Interval (Css-avg)
ng/mLPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C2D1——1397 ± NA5499 ± NA8581 ± NA16115 ± NA———
C3D1—28.3 ± NA556 ± NA4065 ± NA7666 ± NA————
SecondaryAccumulation Index - Area Under Curve (AI-AUC)

Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. The area under curve is defined as the area under the plot of plasma concentration of a drug versus time after dosage which reflects the extent of exposure to a drug and its clearance rate from the body.

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Reported as:
Geometric mean · Ratio
Accumulation Index - Area Under Curve (AI-AUC)
RatioPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C2D1———1.07 ± NA0.856 ± NA0.953 ± NA———
C3D1—0.100 ± NA—0.808 ± NA1.28 ± NA————
SecondaryAccumulation Index - Cmax (AI-Cmax)

Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. (Approximately 31 months)
Reported as:
Geometric mean · Ratio
Accumulation Index - Cmax (AI-Cmax)
RatioPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C2D1—0.475 ± NA—1.19 ± NA0.951 ± NA0.861 ± NA——0.687 ± 23
C3D1—0.457 ± NA0.309 ± NA0.920 ± NA1.11 ± NA0.940 ± NA——1.11 ± NA
C4D1———————0.633 ± NA—
SecondaryAccumulation Index - Concentrations at the End of Dosing Interval (AI-CTAU)

Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose.

Time frame:
Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. (Approximately 31 months)
Reported as:
Geometric mean · Ratio
Accumulation Index - Concentrations at the End of Dosing Interval (AI-CTAU)
RatioPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg
C2D1———0.640 ± NA1.12 ± NA1.38 ± NA———
C3D1—NA ± NA—0.391 ± NA33.3 ± NA————

Adverse events

Collected over Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 50 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 31 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Preliminary - BMS-986226 2 mg5/6 (83.3%)2/6 (33.3%)6/6 (100%)
Preliminary - BMS-986226 8 mg3/7 (42.9%)3/7 (42.9%)7/7 (100%)
Part A - BMS-986226 25 mg5/7 (71.4%)2/7 (28.6%)7/7 (100%)
Part A - BMS-986226 80 mg8/11 (72.7%)10/11 (90.9%)10/11 (90.9%)
Part A - BMS-986226 200 mg5/9 (55.6%)5/9 (55.6%)9/9 (100%)
Part A - BMS-986226 400 mg7/9 (77.8%)9/9 (100%)9/9 (100%)
Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg7/10 (70%)5/10 (50%)10/10 (100%)
Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg8/12 (66.7%)9/12 (75%)12/12 (100%)
Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg5/9 (55.6%)5/9 (55.6%)9/9 (100%)
Total53/80 (66.3%)50/80 (62.5%)79/80 (98.8%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kgTotal
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/62/70/75/114/96/95/106/124/933/80
Intestinal obstructionGastrointestinal disorders0/60/70/71/110/92/90/100/120/93/80
Abdominal painGastrointestinal disorders0/60/70/72/110/91/91/100/120/94/80
PyrexiaGeneral disorders1/60/70/70/110/90/90/100/120/91/80
Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/70/70/110/90/90/100/120/91/80
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60/70/70/110/90/90/100/120/91/80
Pleural effusionRespiratory, thoracic and mediastinal disorders0/60/70/70/110/90/90/102/120/92/80
Rectal haemorrhageGastrointestinal disorders0/61/70/71/110/90/90/100/120/92/80
Blood bilirubin increasedInvestigations0/60/71/70/110/90/90/100/121/92/80
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/71/70/110/90/90/100/120/91/80
Most frequent other events
Showing 10 of 139
Most frequent other events
EventPreliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kgTotal
Infusion related reactionInjury, poisoning and procedural complications0/63/73/75/118/98/94/106/123/940/80
NauseaGastrointestinal disorders1/62/70/71/110/96/93/103/120/916/80
FatigueGeneral disorders2/61/71/74/113/95/93/105/121/925/80
Decreased appetiteMetabolism and nutrition disorders1/61/71/72/110/95/92/103/120/915/80
DiarrhoeaGastrointestinal disorders2/60/70/73/110/94/91/101/120/911/80
Aspartate aminotransferase increasedInvestigations1/63/70/72/111/90/94/103/121/915/80
AnaemiaBlood and lymphatic system disorders1/60/70/73/111/93/92/104/120/914/80
VomitingGastrointestinal disorders1/61/70/70/112/92/91/104/123/914/80
PyrexiaGeneral disorders0/61/71/71/111/93/92/101/120/910/80
Blood creatinine increasedInvestigations0/60/70/70/110/93/90/103/120/96/80

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Preliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kgTotal
Mean59.3 ± 10.458.3 ± 7.863.6 ± 12.362.5 ± 9.755.3 ± 15.961.7 ± 16.955.7 ± 9.662.3 ± 11.758.3 ± 7.159.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Preliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kgTotal
Female12353345228
Male55466667752
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Preliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kgTotal
Hispanic or Latino1110011016
Not Hispanic or Latino55454268544
Unknown or Not Reported01265634330
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Preliminary - BMS-986226 2 mgPreliminary - BMS-986226 8 mgPart A - BMS-986226 25 mgPart A - BMS-986226 80 mgPart A - BMS-986226 200 mgPart A - BMS-986226 400 mgPart C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kgPart C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kgPart C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kgTotal
American Indian or Alaska Native0000000000
Asian1000000001
Native Hawaiian or Other Pacific Islander0000000000
Black or African American0000001023
White4661099712669
More than one race0000000000
Unknown or Not Reported1111002017
08

Study locations

13 sites
  • Local Institution - 0005
    Boston, Massachusetts 02215, United States
  • Local Institution - 0012
    Saint Louis, Missouri 63110, United States
  • Local Institution - 0002
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0001
    Philadelphia, Pennsylvania 19111, United States
  • Local Institution - 0004
    Nashville, Tennessee 37203, United States
  • Local Institution - 0014
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0006
    Hamilton, Ontario L8V 5C2, Canada
  • Local Institution - 0003
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0007
    Madrid, 28040, Spain
  • Local Institution - 0008
    Madrid, 28050, Spain
  • Local Institution - 0009
    Chur, 7000, Switzerland
  • Local Institution - 0010
    Lausanne, 1011, Switzerland
  • Local Institution - 0011
    Zuerich, 8091, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2021, 51 months.

Results were first posted in Feb 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2017
First posted
Aug 16, 2017
StartActual
Sep 1, 2017
Primary completionActual
Dec 20, 2021
CompletionActual
Dec 20, 2021
Results first posted
Feb 28, 2023
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03251924
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Sep 1, 2017
Primary completion
Dec 20, 2021
Completion
Dec 20, 2021
Results posted
Feb 28, 2023
Last update
Feb 28, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion